Walgreens Boots Alliance Competitive Strategy & SWOT Analysis
But the merger, while significant in scale, also introduced complexity that would prove difficult to manage. The company's long-term viability depends on its ability to stabilize its pharmacy economics and find a sustainable role in the evolving American healthcare ecosystem. The Boots Advantage Card loyalty program, with more than 17 million active members, is one of the most deeply embedded retail loyalty schemes in British consumer culture. Boots' No7 skincare brand and Advantage Card loyalty program represent examples of the kind of proprietary value creation that the U.S. Operations have not yet successfully replicated at scale. By fiscal year 2024, CVS Health reported revenues of approximately 372 billion dollars — more than twice Walgreens' consolidated revenue — reflecting the enormous scale advantage that vertical integration delivers. The company is attempting to compete on the basis of pharmacist expertise, physical accessibility, and the unique trust relationship between patients and their local pharmacist — advantages that are real but have proven difficult to monetize at scale in the current reimbursement environment. Despite its current financial difficulties, Walgreens Boots Alliance retains several genuine competitive advantages that represent the foundation upon which any successful turnaround must be built. Network Scale and Geographic Density This vaccination infrastructure — including trained staff, cold storage capabilities, scheduling systems, and public trust — represents a durable advantage in immunization services broadly. Loyalty Program Scale The combined myWalgreens program in the U.S. And the Boots Advantage Card in the UK together enroll more than 120 million members, creating a proprietary first-party data asset of substantial value for targeted marketing, health interventions, and potential data partnership monetization.
SWOT Analysis: Walgreens Boots Alliance
Market Position & Competitive Landscape
Pharmacy benefit managers — the powerful intermediaries that negotiate drug prices between manufacturers, insurers, and pharmacies — were systematically ratcheting down the reimbursement rates that Walgreens and its competitors received for filling prescriptions. This reservoir of brand trust is a real asset that purely transactional competitors cannot acquire quickly. CVS Health: The Integrated Competitor The most formidable direct competitor is CVS Health, which has executed a strategic transformation that Walgreens has attempted but not matched. Amazon's structural advantages in pharmacy are formidable: its logistics infrastructure enables next-day or two-day delivery of most prescriptions across the continental United States; its Prime membership base of more than 200 million subscribers globally provides an enormous captive audience; its technology platform enables smooth digital prescription management; and its capital base allows it to absorb losses in pharmacy while building market share. Costco and Walmart: The Value Competitors While not pharmacy competitors, Dollar General and Dollar Tree have systematically captured the value-oriented consumer who once browsed the front-of-store aisles at Walgreens for household consumables, seasonal merchandise, and snacks. Closing stores disrupts patient-pharmacy relationships, as patients whose pharmacy closes must transfer their prescriptions elsewhere, often choosing a competitor's location over the nearest remaining Walgreens. This proximity advantage is most valuable for urgent prescription needs, same-day medication access, and in-person pharmacist consultation, services that delivery-focused competitors cannot match for patients who need their medication immediately. State-level scope-of-practice expansions are increasingly allowing pharmacists to prescribe certain medications, administer vaccinations, and provide clinical testing services — capabilities that Walgreens pharmacists are already exercising and that differentiate the company from pure-play online competitors. The store was small by modern standards, occupying a modest storefront in a working-class neighborhood, but Walgreen brought to it an energy and innovation that would soon distinguish it from every competitor on the South Side. While other retail pharmacies fought over increasingly expensive urban real estate, Walgreens established itself as the pharmacy of choice for the growing American suburban middle class, a positioning that paid dividends for decades.
Frequently Asked Questions
Who are Walgreens Boots Alliance's main competitors?
Walgreens Boots Alliance faces competition on three fronts. In US retail pharmacy, the principal competitor is CVS Health Corporation, the largest US drugstore chain by revenue and store count (over 9,000 stores) and the owner of pharmacy benefit manager CVS Caremark and insurer Aetna. CVS's vertical integration of insurance, PBM, retail pharmacy, and now primary care (through Oak Street Health and Signify Health) is the structural rival to WBA's strategy. Other US retail pharmacy competitors include Rite Aid (until its 2023 bankruptcy), grocery chain pharmacies (Kroger, Albertsons, Publix), mass merchant pharmacies (Walmart, Target via CVS partnership, Costco), and increasingly Amazon Pharmacy, which launched in November 2020 and offers home delivery of prescription drugs. In the UK, Boots competes against Lloyds Pharmacy (sold by McKesson to Aurelius in 2021), Superdrug, Tesco and Sainsbury's in-store pharmacies, and online pharmacies including Pharmacy2U. In specialty pharmacy and home care, Walgreens' Shields and CareCentrix compete against CVS Specialty, Express Scripts/Accredo, OptumRx Specialty, and Humana CenterWell.
How does WBA compete against CVS Health structurally?
Walgreens Boots Alliance and CVS Health pursue similar omnichannel pharmacy and healthcare strategies but with different vertical integration profiles. CVS Health owns Aetna (acquired 2018 for $69 billion) and the pharmacy benefit manager CVS Caremark, giving it captive insurance lives, prescription routing, and reimbursement-rate setting power inside its own ecosystem. CVS added primary care through the $10.6 billion Oak Street Health acquisition completed in May 2023 and home care through $8 billion Signify Health acquisition in March 2023. WBA chose a different vertical strategy: rather than buying an insurer or PBM, it acquired primary-care provider VillageMD (controlling stake 2021, full majority 2022), Summit Health-CityMD (2023), specialty pharmacy services provider Shields Health Solutions (full ownership 2022), and post-acute home care benefits manager CareCentrix (full ownership 2023). The WBA bet was that owning the providers (primary care, urgent care, specialty pharmacy, post-acute care) would let it negotiate from a position of strength with PBMs and insurers. As of 2025, results favor CVS's strategy: CVS market cap is roughly six times WBA's, and WBA's healthcare bets have generated $12+ billion of impairments.
How is Walgreens responding to Amazon Pharmacy and mail-order competition?
Walgreens Boots Alliance has responded to the Amazon Pharmacy threat through three principal tactics. First, Walgreens accelerated its mail-order and home-delivery capability, expanding free prescription home delivery within 1–2 days through its existing $20 Prescription Savings Club and through partnerships with delivery services including DoorDash and Postmates. Second, it leveraged the physical store network as a same-day pickup advantage, with 78% of Americans living within five miles of a Walgreens; same-day pickup is something Amazon Pharmacy cannot match for prescription drug fills initiated late in the day. Third, it invested in specialty pharmacy services through Shields Health Solutions and AllianceRx Walgreens Specialty to capture high-cost specialty molecules that are typically dispensed through specialty pharmacies rather than retail or mail. Amazon Pharmacy, launched in November 2020 after Amazon's 2018 PillPack acquisition, remains a smaller competitor in terms of total prescription volume (well below 1% of US scripts) but has grown rapidly in cash-pay generics through the Amazon One Medical primary care integration. Walgreens is also exploring direct PBM negotiation reform and the elimination of the most punitive direct and indirect remuneration (DIR) clawback fees.
What role does the Boots beauty business play in WBA's competitive positioning?
The Boots beauty business is a critical differentiator for the WBA International segment and one of the most valuable assets in the WBA portfolio. Boots is the largest seller of beauty and skincare products in the United Kingdom, anchored by its proprietary No7 brand (launched in 1935 and a UK retail icon), Boots-branded haircare, fragrance, and cosmetics, and exclusive UK distribution arrangements with Liz Earle, Soap & Glory, Sleek MakeUP, Botanics, and Champneys, plus prestige brand counters from Estee Lauder, Lancome, Yves Saint Laurent, Clinique, and Charlotte Tilbury inside larger Boots stores. The Boots Advantage Card loyalty program, with over 16 million active members in the UK, provides one of the deepest consumer datasets in British retail and supports targeted marketing of beauty products. Boots also operates beauty-only stores and an extensive e-commerce platform at boots.com. Within WBA, the beauty business delivers materially higher gross margins than commodity pharmacy retail and represents the principal reason WBA repeatedly rejected sub-£5 billion bids for Boots in the 2022 sale process. The unit competes against UK retailers Superdrug, Sephora UK, Cult Beauty, and Beauty Bay, as well as Amazon UK and direct-to-consumer beauty brands.
How is Walgreens shrinking its US store footprint and why?
Walgreens Boots Alliance is shrinking its US store footprint from a peak of approximately 9,560 stores in 2018 to a target near 7,000 stores by 2027, a reduction of nearly 27% of the US network. The closure program was accelerated on 27 June 2024 when CEO Tim Wentworth announced 1,200 additional store closures over three years on top of approximately 1,000 closures already underway since 2019. The economic rationale is straightforward: roughly a quarter of US Walgreens stores were losing money on a cash basis, dragged down by declining prescription volume, retail-front shopper traffic shifting to Amazon and mass merchants, organized retail crime in certain urban markets (which Walgreens repeatedly cited in earnings calls), and lease renewal rates that exceeded what shrinking store-level cash flow could support. The closures disproportionately affect urban communities and pharmacy deserts in cities including Chicago, Boston, San Francisco, and Los Angeles, drawing political criticism. The strategy aims to concentrate Walgreens' remaining capital in profitable stores, accelerate the rollout of Village Medical at Walgreens primary-care clinics in high-traffic locations, and reduce the corporate overhead and supply chain costs of operating a 9,000+ store network.